Beyond the Prescription Count: MASLD, Polypharmacy, and Moving to More Precise Deprescribing - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Rethinking Medication Burden in MASLD: Toward More Targeted Deprescribing

  • By

  • Daniella Lee

  • Alexander Chaitoff

  • November 16, 2026

Share

  • 1

    In a nationally representative NHANES sample, polypharmacy increased with age and was similar by MASLD status across most age groups.

  • 2

    Among adults aged 75 years or older, polypharmacy prevalence was higher with MASLD than without it (60.3% vs 42.7%; P < .01).

  • 3

    Higher medication use in older adults with MASLD may reflect greater cardiometabolic disease burden, but the study cannot determine whether treatment is appropriate or hazardous.

  • 4

    Evidence that reducing medication counts improves clinical outcomes or patient satisfaction remains limited, even when deprescribing targets potentially inappropriate medications.

  • 5

    The authors call for further research and precision approaches to identify which people with MASLD may benefit from individualized deprescribing.

Original Source(s)

Related Content